Finland's institute for health and welfare has said that the country will pause the use of Moderna's (Nasdaq:MRNA) COVID-19 vaccine for men born in 1991 and later due to reports of a rare cardiovascular side effect, Reuters news agency reported on Thursday.
The director of the health institute, Mika Salminen, stated: "A Nordic study involving Finland, Sweden, Norway and Denmark found that men under the age of 30 who received Moderna Spikevax had a slightly higher risk than others of developing myocarditis."
This condition, an inflammation of the heart muscle, usually heals on its own in a few days. However, as a precaution Finland would only give Pfizer's (NYSE:PFE) vaccine to boys and young men, Salminen said.
Sweden and Denmark have suspended the use of the Moderna vaccine for all young adults and children.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins